Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma

Surgery

Volumn 142, Issue 6, 2007, Pages 952-958

  Mirallié, Eric ^a   Guillan, Thomas ^a   Bridji, Boumédiene ^b   Resche, Isabelle ^b   Rousseau, Caroline ^b   Ansquer, Catherine ^c   Bodet Milin, Caroline ^c   Curtet, Chantal ^d   Carnaille, Bruno ^e   Murat, Arnaud ^c   Charbonnel, Bernard ^c   Kraeber Bodéré, Françoise ^b,c,d  

^a IMAD   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c HÔTEL DIEU   (France)

^d INSERM   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; HYPOPARATHYROIDISM; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CARCINOMA; THYROIDECTOMY; TIME SERIES ANALYSIS; WHOLE BODY SCINTISCANNING; ADENOCARCINOMA; BLOOD; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; ONCOCYTOMA; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; THYROID TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA, FOLLICULAR; ADENOMA, OXYPHILIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36649002453     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2007.09.015     Document Type: Article

References (24)

1. Leboulleux S., Rubino C., Baudin E., Caillou B., Hartl D.M., Bidart J.M., et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90 (2005) 5723-5729
2. Eustatia-Rutten C.F., Corssmit E.P., Biermasz M.R., Pereira A.M., Romijn J.A., and Smit J.W. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91 (2006) 313-319
3. Rouxel A., Hejblum G., Bernier M.O., Boelle P.Y., Menegaux F., Mansour G., et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinoma. J Clin Endocrinol Metab 89 (2004) 5362-5368
4. Pineda J.D., Lee T., Ain K., Reynolds J.C., and Robbins J. Iodine-131 therapy for cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80 (1995) 1488-1492
5. Mazzaferri E.L., and Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86 (2001) 1447-1463
6. Torlontano M., Crocetti U., Augello G., D'Aloiso L., Bonfitto N., Varraso A., et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 91 (2006) 60-63
7. Helal B.O., Merlet P., Toubert M.E., Franc B., Schwartz C., Gauthier-Koelesnikov H., et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42 (2001) 1464-1469
8. Palmedo H., Bucerius J., Joe A., Strunk H., Hortling N., Meyka S., et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47 (2006) 616-624
9. Rubello D., Salvatori M., Casara D., Piotto A., Toniato A., Gross M.D., et al. (99m)Tc-sestamibi radio-guided surgery of loco-regional (131)iodine-negative recurrent thyroid cancer. Eur J Surg Oncol 33 (2007) 902-906
10. Antonelli A., Miccoli P., Fallahi P., Ferrari S.M., Grosso M., Boni G., et al. Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children. Surgery 140 (2006) 1035-1041
11. Alam M.S., Kasagi K., Misaki T., Miyamoto S., Iwata M., Ida Y., et al. Diagnostic value of technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation. Thyroid 8 (1998) 1091-1100
12. Wu H.S., Huang W.S., Liu Y.C., Yen R.F., Chen Y.Y., and Kao C.H. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan. Anticancer Res 23 (2003) 4235-4238
13. Stokkel M.P., Verkooijen R.B., and Smit J.W. Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value. Eur J Nucl Med Mol Imaging 31 (2004) 950-957
14. Kraeber-Bodere F., Cariou B., Curtet C., Bridji B., Rousseau C., Dravet F., et al. Feasibility of 18F-FDG-guided surgery in the management of metastases from differentiated thyroid carcinoma with negative 131I uptake. Surgery 138 (2005) 1176-1182
15. Wang W., Macapinlac H., Larson S.M., Yeh S.D., Akhurst T., Finn R.D., et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84 (1999) 2291-2302
16. Shammas A., Degirmenci B., Mountz J.M., McCook B.M., Branstetter B., Bencherif B.B., et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48 (2007) 221-226
17. Hamy A., Mirallié E., Bennouna J., Resche I., Drefty C., Johnstone M., et al. Thyroglobulin monitoring after treatment of well differentiated thyroid cancer. Eur J Surg Oncol 30 (2004) 681-685
18. Chin B.B., Patel P., Cohade C., Ewertz M., Wahl R., and Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89 (2004) 91-95
19. Barbet J., Campion L., Kraeber-Bodere F., and Chatal J.F. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90 (2005) 6077-6084
20. Freudenberg L.S., Antoch G., Jentzen W., Pink R., Knust J., Görges R., et al. Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14 (2004) 2092-2098
21. Teunissen J.J., Kwekkeboom D.J., and Krenning E. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 17 (2006) 19-25
22. Görges R., Kahaly G., Muller-Brand J., Macke H., Roser H.W., and Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 11 (2001) 647-659
23. Baudin E., Schlumberger M., Lumbroso J., Travagli J.P., Caillou B., and Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 81 (1996) 2541-2544
24. Teunissen J.J., Kwekkeboom D.J., Kooij P.P., Bakker W.H., and Krenning E.P. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J Nucl Med 46 Suppl 1 (2005) 107S-114S